In summary, our experiments demonstrate that DS is a brain-penetrant dual PI3K/mTOR inhibitor that exhibits potent anticancer activity as a single agent in preclinical glioma models and further enhances the effects of TMZ in human glioma xenografts, which supports the benefit of combining two therapeutic modalities that have entirely different mechanisms of activity. Here, PIK3CD is linked to central nervous system cancer.